𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients

✍ Scribed by Kaan Tunceli; Shiva G. Sajjan; Dena R. Ramey; David R. Neff; Andrew M. Tershakovec; X. Henry Hu; Joanne E. Tomassini; JoAnne M. Foody

Book ID
119287934
Publisher
Elsevier
Year
2010
Tongue
English
Weight
569 KB
Volume
4
Category
Article
ISSN
1933-2874

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Age, Abdominal Obesity, and Baseline Hig
Age, Abdominal Obesity, and Baseline High-Sensitivity C-Reactive Protein Are Associated with Low-Density Lipoprotein Cholesterol, non–High-Density Lipoprotein Cholesterol, and ApoB Responses to Lipid-Lowering Therapy in Patients with Metabolic Syndrome and Moderately High/High Coronary Heart Disease Risk†
✍ Jennifer G. Robinson; Christie M. Ballantyne; Willa A. Hsueh; Jeffery B. Rosen; πŸ“‚ Article πŸ“… 2012 πŸ› Elsevier 🌐 English βš– 63 KB
Effects of Ezetimibe Added to Atorvastat
Effects of Ezetimibe Added to Atorvastatin Versus Atorvastatin Up-Titration on Attainment of Single and Dual Levels for Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, or High-Sensitivity C-Reactive Protein in Older Adults with High Coronary Heart Disease Risk
✍ Christian Constance; Ori Ben-Yehuda; Nanette K. Wenger; Franklin Zieve; Jianxin πŸ“‚ Article πŸ“… 2010 πŸ› Elsevier 🌐 English βš– 50 KB